Option chain shows key data for Advent Technologies Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Advent Technologies Hldgs.

Advent Technologies Hldgs (NASDAQ:ADN) Stock, Option Chain

Advent Technologies Hldgs

Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.

Wall-Street-ai7-1

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

EFSH

NGNE

NUWE

YUMC

S&amp;P 500 Edges Lower; Yum China Earnings Top Views

opec oil shutter

Intraday Update

Crude Oil Gains 3%; Constellation Energy Shares Tumble After Q3 Results

Wall Street

SPPL

Dow Falls Over 200 Points; Marriott Posts Downbeat Earnings

Advent Technologies Holdings, Inc. - Class A Common Stock

Advent Technologies Holdings Inc

AIDA ENGINEERING LTD ORD by Aida Engineering, Ltd.

Aida Engineering Ltd

Adient PLC

Advent Technologies Holdings, Inc. - Warrant

Citigroup analyst Jason Gursky initiates coverage on Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Buy rating and announces Price Target of $410.

Price Target

Initiation

Analyst Ratings

Citigroup Initiates Coverage On Curtiss-Wright with Buy Rating, Announces Price Target of $410

General

ADEA

Adeia Extends Multi-Year IP License Agreement With Roku

Morgan Stanley analyst Hamza Fodderwala maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and raises the price target from $223 to $230.

PANW

Morgan Stanley Maintains Overweight on Palo Alto Networks, Raises Price Target to $230

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst John Glass downgraded the rating for Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) from Overweight to Equal-Weight and lowered the price target from $158 to $140. Yum Brands shares closed at $125.32 on Friday. <a href="https://www.benzinga.com/quote/YUM/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Kyle Mcnealy downgraded Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Hold to Underperform and lowered the price target from $211.84 to $200.75. Apple shares closed at $229.98 on Friday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Alex Straton downgraded Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Overweight to Equal-Weight and cut the price target from $164 to $140. Ross Stores shares closed at $149.15 on Friday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Benjamin Theurer downgraded the rating for Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) from Overweight to Equal-Weight and lowered the price target from $115 to $95. Bunge Global shares closed at $79.54 on Friday. <a href="https://www.benzinga.com/quote/BG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Benjamin Theurer downgraded CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) from Overweight to Equal-Weight but raised the price target from $96 to $100. CF Industries shares closed at $97.01 on Friday. <a href="https://www.benzinga.com/quote/CF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="564" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-1024x564.png" alt="" class="wp-image-742291" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-1024x564.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-768x423.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43091705/top-4-health-care-stocks-you-may-want-to-dump-in-q1">Top 4 Health Care Stocks You May Want To Dump In Q1</a></li>
</ul>

Downgrades

Pre-Market Outlook

AAPL

ROST

This Apple Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Citigroup analyst Jason Gursky upgrades RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) from Neutral to Buy and raises the price target from $132 to $153.

Upgrades

Citigroup Upgrades RTX to Buy, Raises Price Target to $153

– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315
– Posters highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance
WEST CHESTER, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrca#NASDAQ">VRCA</a>), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the presentation of three posters that were presented at the 2025 Winter Clinical Dermatology Conference, which was held from January 17-19, in Miami, Florida. The posters featured clinical data from Part 2 of the Phase 2 study (the "Study") of the Company's novel oncolytic peptide, VP-315, for the treatment of basal cell carcinoma ("BCC").
Verrica presented a poster titled "Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC)" while encore presentations of two additional posters (titled "Results of a Phase 2 Multicenter Study Evaluating the Safety and Tolerability of VP-315, an Investigational therapy for Basal Cell Carcinoma" and "Results of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational Therapy for Basal Cell Carcinoma") were also made at the conference. The posters included safety and histologic clearance data from 82 patients with up to two target BCC tumors (a total of 91 tumors) in Part 2 of the Study evaluating VP-315 for the treatment of BCC, including patients with tumors on the head and neck.
Part 2 of the Study was designed to explore dosing regimens to help Verrica identify the recommended regimen for a Phase 3 study program. Approximately 51% of tumors treated in the Study achieved complete histological clearance, while those patients with a residual tumor achieved, on average, approximately 71% reduction in tumor size. There were no Treatment Related Serious Adverse Events, and most Treatment Related Adverse Events were mild to moderate.
In the newly-presented poster, Verrica conducted a post-hoc analysis of the data from the Study and announced a Calculated ORR of 97%, defined as the percentage of study subjects who do not demonstrate disease progression and who experience at least a 30% level of tumor reduction along with partial or complete response following treatment The Company still expects genomic and T-cell (immune response) data in the first quarter of 2025 and plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine the next steps for the development of VP-315 for the treatment of BCC.

Penny Stocks

VRCA

Verrica Pharmaceuticals To Present 3 Posters Featuring Preliminary Topline Results Of VP-315 For The Treatment Of Basal Cell Carcinoma, Including A 97% Calculated Objective Response Rate Of Study Subjects Following Treatment With VP-315 At The 2025 Winter Clinical Dermatology Conference

<h3>Gainers</h3>
<ul>
<li>Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) shares rose 17.7% to $8.39 during Tuesday's pre-market session. The company's market cap stands at $218.1 million. </li>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) stock moved upwards by 14.52% to $2.01. The market value of their outstanding shares is at $14.1 million. </li>
<li>Premium Catering (Hldgs) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PC#NASDAQ">PC</a>) stock moved upwards by 11.21% to $0.8. The market value of their outstanding shares is at $12.8 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) stock moved upwards by 9.89% to $0.53. The market value of their outstanding shares is at $7.9 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock rose 8.26% to $2.49. The market value of their outstanding shares is at $9.7 million. </li>
<li>Zapp Electric Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) shares moved upwards by 8.03% to $1.21. The company's market cap stands at $5.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Canoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) stock declined by 73.4% to $0.36 during Tuesday's pre-market session. The company's market cap stands at $5.1 million. </li>
<li>New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) stock declined by 12.56% to $53.2. The market value of their outstanding shares is at $8.6 billion. The company's, Q2 earnings came out today. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) stock fell 8.91% to $0.64. The company's market cap stands at $4.3 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock declined by 8.36% to $0.67. The market value of their outstanding shares is at $14.1 million. </li>
<li>Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) shares fell 6.59% to $126.6. The market value of their outstanding shares is at $34.7 billion. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock decreased by 6.49% to $2.74. The company's market cap stands at $9.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALUR

AYRO

CJET

New Oriental Education & Technology Group

GDHG

GOEV

VEEE

ZAPP

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 47.8% to $1.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares increased by 36.89% to $2.56. The market value of their outstanding shares is at $3.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares rose 19.82% to $1.39. The market value of their outstanding shares is at $3.8 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock increased by 19.75% to $6.75. The company's market cap stands at $8.6 million. </li>
<li>Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) shares rose 19.14% to $41.88. The company's market cap stands at $6.5 billion. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) stock rose 17.39% to $5.94. The company's market cap stands at $336.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares declined by 14.1% to $7.6 during Tuesday's pre-market session. The market value of their outstanding shares is at $276.3 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares fell 12.47% to $0.13. The market value of their outstanding shares is at $10.7 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock decreased by 10.94% to $0.57. The company's market cap stands at $10.4 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock fell 10.64% to $2.52. The market value of their outstanding shares is at $124.9 million. </li>
<li>Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) shares fell 9.76% to $1.11. The company's market cap stands at $47.7 million. </li>
<li>Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) stock decreased by 9.1% to $310.0. The company's market cap stands at $8.8 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

AKYA

BDMD

BMRA

DSGN

DWTX

HSDT

RDHL

RPID

TNFA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) shares increased by 22.5% to $6.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $83.0 million. </li>
<li>Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) stock moved upwards by 10.64% to $16.32. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) shares moved upwards by 9.69% to $4.3. The company's market cap stands at $212.2 million. </li>
<li>ACCO Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACCO#NYSE">ACCO</a>) shares rose 9.42% to $5.69. The market value of their outstanding shares is at $544.1 million. </li>
<li>Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) shares increased by 7.44% to $3.61. The company's market cap stands at $399.1 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares increased by 6.97% to $0.44. The company's market cap stands at $10.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Graphex Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) stock decreased by 15.9% to $0.26 during Tuesday's pre-market session. The company's market cap stands at $15.2 million. </li>
<li>Nocera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) stock declined by 8.26% to $1.0. The market value of their outstanding shares is at $14.0 million. </li>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares decreased by 6.46% to $0.87. The company's market cap stands at $311.1 million. </li>
<li>Staffing 360 Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares fell 5.94% to $3.17. The company's market cap stands at $4.8 million. </li>
<li>Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) shares decreased by 5.71% to $2.81. The market value of their outstanding shares is at $152.2 million. </li>
<li>Multi Ways Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MWG#AMEX">MWG</a>) stock decreased by 5.58% to $0.27. The market value of their outstanding shares is at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCO

AMPX

BAER

CRGO

GRFX

NCRA

PSIG

STAF

VATE

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) stock rose 19.9% to $1.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $16.3 million. </li>
<li>Logility Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) shares increased by 12.52% to $12.4. The company's market cap stands at $417.6 million. </li>
<li>Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) stock moved upwards by 10.44% to $2.22. The company's market cap stands at $638.7 million. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) stock increased by 9.85% to $1.56. The market value of their outstanding shares is at $130.3 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock moved upwards by 9.59% to $8.45. The market value of their outstanding shares is at $130.3 million. </li>
<li>WISeKey Intl Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) stock increased by 8.69% to $8.0. The market value of their outstanding shares is at $89.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock decreased by 25.0% to $0.84 during Tuesday's pre-market session. The company's market cap stands at $19.4 million. </li>
<li>BTC Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) stock decreased by 10.9% to $7.36. The market value of their outstanding shares is at $38.6 million. </li>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) stock declined by 10.08% to $2.32. The market value of their outstanding shares is at $57.2 million. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock declined by 8.5% to $0.86. </li>
<li>CISO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) stock declined by 7.77% to $0.95. The company's market cap stands at $11.2 million. </li>
<li>Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) stock declined by 6.84% to $12.0. The company's market cap stands at $50.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTCT

CISO

INLX

LGTY

ORKT

PCLA

SatixFy Communications Ltd. Ordinary Share

SATX

SOBR

WKEY

XTKG

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

Old National Bancorp Reported Q4 Return On Average Tangible Common Equity Of 16.4%; Adjusted Of 17.0%, With Preliminary Regulatory Tier 1 Common Equity To Risk-weighted Assets Of 11.38%, Up 38 BPS

Needham analyst Ryan Koontz reiterates Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) with a Buy and maintains $5.5 price target.

Reiteration

LTRX

Needham Reiterates Buy on Lantronix, Maintains $5.5 Price Target

Contracts

GILT

Gilat Bags $5M To Improve Defense Forces Connectivity

Citigroup analyst Jason Gursky initiates coverage on V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) with a Buy rating and announces Price Target of $64.

Citigroup Initiates Coverage On V2X with Buy Rating, Announces Price Target of $64

Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.46 by 6.52 percent. This is a 6.52 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $489.95 million which beat the analyst consensus estimate of $485.57 million by 0.90 percent. This is a 5.48 percent increase over sales of $464.50 million the same period last year.

Old National Q4 2024 Adj EPS $0.49 Beats $0.46 Estimate, Sales $489.95M Beat $485.57M Estimate

Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.61 by 42.62 percent. This is a 70.59 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $31.90 million which beat the analyst consensus estimate of $29.49 million by 8.17 percent. This is a 11.50 percent increase over sales of $28.61 million the same period last year.

Earnings Beats

GNTY

Guaranty Bancshares Q4 EPS $0.87 Beats $0.61 Estimate, Sales $31.90M Beat $29.49M Estimate

WIIM

3M shares are trading higher following better-than-expected Q4 EPS and revenues.

Needham analyst Ryan Koontz reiterates AudioCodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) with a Buy and maintains $11 price target.

AUDC

Needham Reiterates Buy on AudioCodes, Maintains $11 Price Target

Citigroup analyst Jason Gursky upgrades Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) from Neutral to Buy and maintains the price target from $587 to $587.

Citigroup Upgrades Northrop Grumman to Buy, Maintains Price Target to $587

SCLX

Scilex Holding Company Will File Supplemental New Drug Application With FDA For ELYXYB In Acute Pain Indication

Advent Technologies Holdings, Inc. (ADN) Q4 2023 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Advent Technologies Hldgs (NASDAQ:<a href="https://investorplace.com/stock-quotes/adn-stock-quote/">ADN</a>) just reported results for the fourth quarter of 2023.<ul><li>Advent Technologies Hldgs reported earnings per share of -$10.32.</li><li>The company reported revenue of $1.51 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/adn-stock-earnings-advent-technologies-hldgs-for-q4-of-2023/">ADN Stock Earnings: Advent Technologies Hldgs Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ADN Stock Earnings: Advent Technologies Hldgs Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Advent Technologies Hldgs (NASDAQ:<a href="https://investorplace.com/stock-quotes/adn-stock-quote/">ADN</a>) just reported results for the fourth quarter of 2023.<ul><li>Advent Technologies Hldgs reported earnings per share of -$10.32.</li><li>The company reported revenue of $1.51 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/adn-stock-earnings-advent-technologies-hldgs-for-q4-of-2023/">ADN Stock Earnings: Advent Technologies Hldgs Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Advent Technologies receives Nasdaq notice

Advent Technologies Holdings (ADN) has shared an update. Advent Technologies Holdings, Inc. has addressed one compliance issue by filing its overdu...

Advent Technologies Strives for Nasdaq Compliance Amid Reporting Delays

Advent Technologies: Circling The Drain - Sell

According to a regulatory filing, on October 24, 2024, the Board of Directors of Advent Technologies (ADN) Holdings approved the termination of the...

Advent Technologies board approves termination of Vassilios Gregoriou as CEO

Advent Technologies (ADN) announced changes to its board and C-suite by removing Chairman and CEO Vasilis Gregoriou and Chief Strategy Officer Chri...

Advent Technologies appoints Gary Herman as Interim CEO

Advent Technologies Holdings ( ($ADN) ) has issued an update. Advent Technologies Holdings, Inc. terminated its Securities Purchase Agreement with ...

Advent Technologies Revises Board Amid Agreement Termination

Advent Technologies (ADN) announced that its H2VE proposal has passed the evaluation process. Advent's technical team of Anastasia Koutsomitopoulou...

Advent Technologies awarded grant for H2VE proposal

ADNWW

Press Releases

Advent Technologies Reports Q1 2024 Results

Advent Technologies Reports Q2 2024 Results

Advent Technologies Announces Breakthroughs in Membrane Electrode Assembly Technology

Management

Advent Technologies Announces Management and Board Changes

Advent Technologies' Greek Subsidiary Awarded Grant from EU Innovation Fund for RHyno Project

Financing

Advent Technologies' RHyno Project awarded €34.5 Million by EU Innovation Fund

Advent Technologies' Greek subsidiary, Advanced Energy Technologies S.A. announces changes to its Board of Directors

George Paloumpis Rejoins Advent Technologies as Chief of Operations of its Patras Facility

Advent Technologies Awarded Grant for H2VE Proposal

Advent Technologies Proudly Supports the Wounded Warrior Project

Asia Pacific Wire & Cable Corporation Limited - Common shares, Par value .01 per share

Comments

Advent Technologies Hldgs

Advent Technologies Hldgs (ADN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga